Increased expression of the interferon-inducible dsRNA-activated protein kinase, PKR, has been reported in acute leukemia and solid tumors but the role of PKR has been unclear. Now our results indicate that high PKR expression in CD34+ cells of AML patients correlates with worse survival and shortened remission duration. Significantly, we find that PKR has a novel and previously unrecognized nuclear function to inhibit DNA damage response signaling and double-strand break repair. Nuclear PKR antagonizes ATM activation by a mechanism dependent on PP2A activity. Thus, inhibition of PKR expression or activity promotes ATM activation, γ-H2AX formation and phosphorylation of NBS1 following IR. PKR transgenic but not PKR null mice demonstrate a mutator phenotype characterized by radiation-induced and age-associated genomic instability that was partially reversed by short-term pharmacological PKR inhibition. Furthermore, the age-associated accumulation of somatic mutations that occurs in the Nup98-HOXD13 (NHD13) mouse model of leukemia progression was significantly elevated by co-expression of a PKR transgene while knockout of PKR expression or pharmacological inhibition of PKR activity reduced the frequency of spontaneous mutations in vivo. Thus, PKR cooperated with the NHD13 transgene to accelerate leukemia progression and shorten survival. Taken together these results indicate that increased nuclear PKR has an oncogenic function that promotes the accumulation of potentially deleterious mutations. Thus, PKR inhibition may be a therapeutically useful strategy to prevent leukemia progression or relapse and improve clinical outcomes.
Introduction
The dsRNA-activated protein kinase, PKR, can be activated by a variety of cellular stresses to play a pivotal role in proapoptotic and inflammatory signaling pathways [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . Due to proapoptotic functions, PKR has been considered to have tumor suppressor properties.
However, PKR knockout mice (PKRKO) do not display any increased tumor incidence 12 . In addition, we recently discovered that mice expressing a PKR transgene specifically in hematopoietic cells (TgPKR) develop a preleukemic, myelodysplastic syndrome (MDS)-like phenotype that includes BM dysplasia and increased BM blasts 3 . Furthermore, increased PKR has been reported in patients with acute leukemias, as well as breast, melanoma and colon cancers [13] [14] [15] [16] [17] . Thus, PKR may have a previously unrecognized role that contributes to oncogenesis.
While PKR's role in the cytoplasm to inhibit protein synthesis has been well studied, at least 20% of PKR resides in the nucleus but the function of nuclear PKR is unclear 18 .
Increased nuclear PKR activity is found in CD34+ blasts from high-risk MDS patients but not from low-risk MDS patients or healthy donors, and PKR is mainly nuclear in PTEN-deficient acute leukemia cell lines, suggesting that nuclear PKR signaling may play a role in tumorigenesis 17, 19, 20 . Since we recently observed that Lineage-negative (Lin-) cells isolated from bone marrow (BM) of TgPKR mice are more sensitive, while cells from PKRKO mice are highly resistant to genotoxic stresses including ionizing irradiation 3 , we investigated whether nuclear PKR may regulate DNA damage response (DDR) signaling and whether decreased PKR expression/activity may safeguard genomic fidelity.
For personal use only. on April 13, 2017 . by guest www.bloodjournal.org RPPA processing and statistical analysis was performed as described 21, 22 . In addition, CD34+ cells were isolated from an independent set of 6 randomly selected AML patients by positive selection using a CD34 MicroBead Kit (Miltenyi Biotec; Auburn CA), and primary human CD34+ isolated from the BM of healthy donors were purchased from Lonza (Walkersville MD). Measurement of PKR gene expression in CD34+ AML and normal cells is described in the supplemental methods.
Mice:
C57BL/6-Tg(Vav-NUP98/HOXD13) mice (NHD13) were purchased from Jackson Laboratories (#010505; Bar Harbor, Maine). PKR (TgPKR) and PKR knockout (PKRKO) mice were described previously 3 . Breeding to generate NHD13-TgPKR and NHD13-PKRKO, genotyping and analysis of PB and BM for evidence of MDS/leukemia is described in supplemental methods. In addition, treatment of mice with PKR inhibitor is described in supplemental methods. The University of Florida IACUC approved these experiments (#201102224 and 201208669).
Cell Lines, antibodies and other reagents:
For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From 5 REH, K562 and HL60 cells were from ATCC (Manassas, VA) and propagated under standard growth conditions 11 . Generation of cell lines expressing sh-RNA is described in the supplemental methods. PKR inhibitor compound (PKRI), okadaic acid and anti-phospho-ATM (serine1981) antibody, clone 10H11.E12 were purchased from EMD Millipore (Darmstadt, Germany). FTY720 was obtained from Cayman Chemical Company (Ann Arbor, MI). Antibodies for: Actin, HSP90 PP2A/C, PP2A-B55α and PP2A-B56γ were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Phospho-PKR(threonine451) antibody was purchased from Invitrogen/Biosource (Grand Island, NY).
Antibodies for H2AX, γ -H2AX, ATM, LSD1, NBS1, and phospho-NBS1(serine343) were purchased from Cell Signaling Technology (Beverly, MA).
Flow cytometry:
Staining of surface antigens was performed as described 
Immunofluorescence (IF) microscopy:
Cell cytospins were prepared, fixed with 4% paraformaldehyde for 30 min., permeabilized with 1% Triton in PBS for 10 min. and stained with a 1:30 dilution of the indicated primary antibody and 1:100 dilution of fluorochrome-conjugated secondary antibody. Slides were mounted with Prolong Zeiss Axioplan 2 microscope equipped with epifluorescence optics at 63X. Images were captured using Openlab 5.
Nuclear fractionation, immunoblotting and immunoprecipitation:
Nuclear and cytoplasmic subcellular fractions were prepared using a NE-PER kit according to the manufacturer's protocol (Pierce, Rockford, IL). SDS-PAGE and immunoblotting was performed as previously described 11 . For immunoprecipitation (IP), 500μg of protein lysate was pre-cleared with nonspecific mouse IgG and protein G then incubated overnight with the indicated antibody (1:100 dilution) and protein G agarose (Life Technologies; Grand Island, NY ) at 4°C. Agaroseconjugated complexes were washed with PBS and detected by immunoblotting as described 11 . PP2A was immunoprecipitated from nuclear extracts and activity assayed using a PP2A immunoprecipitation phosphatase kit (17-313, Millipore; Billerica, MA) according to the manufacturer's protocol and as previously described 11 .
Measurement of DNA repair following IR:
DNA repair was quantified using a CometAssay kit and neutral conditions according to the manufacture's protocol (Trevigen, Gaithersburg, MD). SYBR green-stained slides were observed at 40X by fluorescence microscopy using the equipment and software described above. Comet Olive tail moment calculations were performed on 50 randomly chosen cells for each sample by Wimasis Image analysis (Munich, Germany).
Statistical analysis:
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Data is presented as the mean ± SEM of at least 3 independent experiments. Significance (P < 0.05) was determined by student t-test using Prism 6 (GraphPad Software, La Jolla CA). KaplanMeier analysis and Cox proportional hazard modeling were performed on RPPA results using Statistica Version 10 (StatSoft). Kaplan-Meier and Log-rank analysis of mice were performed using Prism 6.
Results

PKR expression correlates with inferior survival and shorter remission duration for AML patients
Increased PKR expression and activity have been reported in leukemia patient samples and leukemia-derived cell lines 16, 17, 20 . To elucidate the role of PKR in leukemia, we tested whether PKR expression may be associated with clinical outcome by RPPA analysis of primary CD34+ blast cells from 414 newly diagnosed AML patients 22, 23 . When stratified for PKR, AML patients with the highest 1/3rd of PKR expression in CD34+ cells had a significantly worse overall survival than patients with the lowest 2/3rds PKR expression ( Figure 1A , median survival 41.6 vs. 54.6 weeks, P < 0.05). [13] [14] [15] [16] . Since PKR's reported proapoptotic function cannot readily account for these findings, we examined whether PKR may have a previously unrecognized oncogenic function.
PKR inhibits DNA damage response signaling
Since we previously demonstrated that cells from PKRKO mice or treated with a pharmacological PKR inhibitor (PKRI) are resistant to genotoxic stress 
Nuclear PKR promotes PP2A-dependent ATM dephosphorylation
Our laboratory and others have demonstrated that PKR can activate protein phosphatase 2A (PP2A), which has been reported to inhibit autophosphorylation and activation of ATM 8, 9, 11, 28
. Thus, we tested whether nuclear PKR may inhibit ATM by a mechanism dependent on PP2A.
PKR efficiently co-precipitated with PP2A from the nuclear fraction of REH and K562 cell lysates, and this interaction was significantly decreased following IR ( Figure 4A ). Furthermore, cells with knocked-down PKR expression (sh-PKR) had an approximately 2-fold decrease in nuclear PP2A activity, suggesting that PKR is necessary to maintain steady-state nuclear PP2A activity ( Figure 4B ). To determine whether increased PKR may accelerate leukemia progression, we crossed TgPKR or PKRKO mice with the NUP98-HOXD13 (NHD13) mouse model of leukemia to produce Overall survival of NHD13-TgPKR mice was significantly shorter, while survival of NHD13-PKRKO mice was significantly longer than that of NHD13 mice ( Figure 6A ). Furthermore, NHD13-TgPKR mice had a higher incidence of leukemia than the NHD13 mice ( Figure 6B ). Conversely, knockout of PKR delayed but did not prevent leukemia development ( Figure 6A and 6B). In addition, endogenous PKR expression was significantly increased (RQ > 2) with age in NHD13 mice that developed acute leukemia and had shortened survival ( Figure 6C and Supplemental Figure 4B ).
PKR accelerates leukemogenesis in a mouse model of leukemia
When BM of mice was examined at a time prior to the development of acute leukemia, NHD13 mice exhibited an age-associated increase in BM blasts that was further elevated by the PKR transgene ( Figure 6D ). In contrast, at 6 months of age the NHD13-PKRKO mice had significantly reduced BM blasts and increased CFU-GEMM frequency compared to NHD13 mice ( Figure 6E) . Consequently, PKRKO mice demonstrated increased PB cell counts and reduced inhibition of myeloid differentiation 
PKR inhibition prevents the accumulation of somatic mutations in vivo
Since PKR inhibition promoted DDR signaling and DSB repair in vitro, we tested whether PKR may affect the frequency of somatic mutations in vivo. Mutation frequency was measured using the PIG-A assay that detects loss of CD24 on murine reticulocytes and is representative of spontaneous mutations that occur in hematopoietic stem and progenitor cells 35, 37, 38 .
At all ages examined, reticulocytes from TgPKR mice had a significantly increased PIG-A mutation frequency compared to WT mice ( Figure 7A) . Furthermore, the age-associated increase in mutation frequency from 3 to 12 months was enhanced by TgPKR but significantly reduced by knockout of PKR ( Figure 7A) . Similarly, PB cells of NHD13-TgPKR mice demonstrated a significantly higher, while those of NHD13-PKRKO mice had a significantly reduced, age-associated increase of the PIG-A mutation frequency compared to NHD13 mice ( Figure 7B ). In addition, reticulocytes of TgPKR mice had a significantly greater mutation frequency than WT mice at 1 week after IR, and did not recover to the low mutation frequency observed in WT mice at 4 weeks after IR ( Figure 7C ). In contrast, PKRKO mice displayed a reduced mutation frequency compared to WT mice following IR ( Figure 7C ). Thus, increased PKR expression promoted a mutator phenotype while knockout of PKR expression reduced the frequency of mutations in vivo. 
Discussion
Our results demonstrate that nuclear PKR has an unexpected pro-oncogenic function to inhibit DDR signaling and DSB repair that can lead to the accumulation of age-associated or irradiation- Our findings demonstrate that PKR has an important and previously unrecognized nuclear function to antagonize ATM activation. Significantly, ATM and PKR co-precipitated in nuclear extracts and PKR activity was required for this interaction. Furthermore, PKR-ATM association was lost upon irradiation. Our findings suggest that PKR antagonizes ATM function by activating PP2A. Other reports suggest that PP2A maintains ATM in a catalytically quiescent state in undamaged cells 28, 42 . Significantly, we observed that PKR inhibition reduced nuclear PP2A activity and nuclear localization of the PP2A B55α regulatory subunit. Whether B55α is a direct downstream target of PKR remains undetermined. In addition, knockdown of PKR resulted in reduced co-precipitation of ATM with PP2A, implying that PKR may regulate PP2A-ATM interaction. Thus, we propose that PKR promotes nuclear B55α localization necessary for nuclear PP2A activity and PP2A-ATM association, which functionally suppresses ATM autophosphorylation in undamaged cells. In response to genotoxic stress including IR, PP2A and ATM rapidly dissociate, allowing ATM autophosphorylation and initiation of the DDR signaling cascade ( Figure 4I ). These results have now prompted us to reinterpret previous findings that inhibition of PKR promotes cell survival following treatment with genotoxic agents, such as doxorubicin, exclusively due to decreased apoptosis. We now propose that inhibition of PKR expression/activity may also promote increased cell survival due to an improved DNA repair capacity that results in a more effective response to genotoxic stress. Significantly, these results suggest that increased PKR expression/activity such as observed in acute leukemia and other cancers may cooperate with other more potent oncogenes to accelerate tumorigenesis. For 627-33.
For For Kaplan-Meier analysis was used to measure: (A) overall survival probability of all patients (n = 414), (B) remission duration for those patients that achieved complete remission (n = 230), (C) survival probability for those patients with unfavorable cytogenetics (n = 195) and (D) remission duration of patients with unfavorable cytogenetics (n =80). Medians (weeks) and P value for each group were calculated by Cox proportional hazard modeling. BM of NHD13 mice that received continuous PKRI treatment had significantly greater CFU-GEMM and total CFU activity.
